MAYTANSINE

MAYTANSINE is a lipid of Polyketides (PK) class. Maytansine is associated with abnormalities such as Myelosuppression and BOSLEY-SALIH-ALORAINY SYNDROME. The involved functions are known as Mutation, Agent, Polymerization, Cell Cycle Arrest and Drug Kinetics. Maytansine often locates in Cytoplasm, Hepatic, Lysosomes, Cell surface and Microtubules. The associated genes with MAYTANSINE are ABCB1 gene, HM13 gene, CNN1 gene, CYP2C8 gene and CYP2D6 gene. The related lipids are Valerates. The related experimental models are Xenograft Model.

Cross Reference

Introduction

To understand associated biological information of MAYTANSINE, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with MAYTANSINE?

MAYTANSINE is suspected in Myelosuppression, BOSLEY-SALIH-ALORAINY SYNDROME and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with MAYTANSINE

MeSH term MeSH ID Detail
Breast Neoplasms D001943 24 associated lipids
Lung Neoplasms D008175 171 associated lipids
Pancreatic Neoplasms D010190 77 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Mammary Neoplasms, Experimental D008325 67 associated lipids
Body Weight D001835 333 associated lipids
Prostatic Neoplasms D011471 126 associated lipids
Melanoma D008545 69 associated lipids
Brain Diseases D001927 27 associated lipids
Leukemia P388 D007941 43 associated lipids
Per page 10 20 | Total 17

PubChem Associated disorders and diseases

What pathways are associated with MAYTANSINE

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with MAYTANSINE?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with MAYTANSINE?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with MAYTANSINE?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with MAYTANSINE?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with MAYTANSINE?

Xenograft Model

Xenograft Model are used in the study 'IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors.' (Ab O et al., 2015).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with MAYTANSINE

Download all related citations
Per page 10 20 50 100 | Total 611
Authors Title Published Journal PubMed Link
Tanida S et al. Ansamitocin-induced synchrony in Tetrahymena pyriformis. 1980 J. Gen. Microbiol. pmid:6777454
Franklin R et al. A phase I-II study of maytansine utilizing a weekly schedule. 1980 Cancer pmid:7214295
Friedkin M and Rozengurt E The role of cytoplasmic microtubules in the regulation of the activity of peptide growth factors. 1980 Adv. Enzyme Regul. pmid:7039258
Chahinian AP et al. Phase I study of weekly maytansine given by iv bolus or 24-hour infusion. 1979 Nov-Dec Cancer Treat Rep pmid:526928
Creagan ET et al. Phase II evaluation of maytansine in patients with advanced head and neck cancer. 1979 Nov-Dec Cancer Treat Rep pmid:526939
Tanida S et al. Inhibition of cilia regeneration of Tetrahymena by ansamitocins, new antitumor antibiotics. 1979 Antimicrob. Agents Chemother. pmid:475367
Rao PN et al. Cell cycle phase-specific cytotoxicity of the antitumor agent maytansine. 1979 Cancer Res. pmid:455300
Cabanillas F et al. Results of a phase II study of maytansine in patients with breast carcinoma and melanoma. 1979 Cancer Treat Rep pmid:371803
Ghetti B Induction of neurofibrillary degeneration following treatment with maytansine in vivo. 1979 Brain Res. pmid:581857
Aldrich CD Pleiotropic phenotype of cultured murine cells resistant to maytansine, vincristine, colchicine, and adriamycin. 1979 J. Natl. Cancer Inst. pmid:224236